Guest guest Posted May 19, 2004 Report Share Posted May 19, 2004 (NOTE: Regeneron was a funder and provided the NT-3 used in the successful human trials for CMT 1A that we received last Fall and have followed for a long time ~ Gretchen) Regeneron to Webcast Presentation at Banc of America Securities Healthcare Conference TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 18, 2004--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Banc of America Securities Healthcare Conference on Friday, May 21, 2004. Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, will provide an overview of the Company and its clinical programs and answer questions from Banc of America Securities' biotechnology analysts. The presentation is scheduled to be broadcast live on Friday, May 21, 2004 at 4:20 p.m. (Eastern Time). The session may be accessed through the Company's website (www.regeneron.com on the Events page, under the Investor heading) at the time of the presentation. An archived version will be available, after the live webcast, until June 4, 2004. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, rheumatoid arthritis, asthma, and obesity and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's Worldwide Web Home Page at www.regeneron.com. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.